deltatrials
Completed PHASE3 NCT00000586

Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Anemia, Sickle Cell Hematologic Diseases Hemoglobinopathies
Interventions hydroxyurea
Updated 5 times since 2017 Last updated: Apr 13, 2016 Started: Jan 31, 1992 Primary completion: Jun 30, 1994 Completion: Jun 30, 1994

A PHASE3 clinical study on Anemia, Sickle Cell and Hematologic Diseases, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 5 data snapshots since 1992. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jan 1992

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.